Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib-II, Non-randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With modFOLFIRINOX for Front-line Treatment of Metastatic Pancreatic Adenocarcinoma (NOVOFFOX)

NCT07284277 is registered in ClinicalTrials.gov with Clinica Universidad de Navarra, Universidad de Navarra as lead sponsor.

NCT NCT07284277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib-II, Non-randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With modFOLFIRINOX for Front-line Treatment of Metastatic Pancreatic Adenocarcinoma (NOVOFFOX)
Lead sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 14, 2025
Completion date
March 31, 2027
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma metastatic, pancreatic ductal adenocarcinoma